**Core Concept**
Dihydroergotamine and ergotamine are both ergot alkaloids used in the treatment of migraine headaches. They have similar mechanisms of action, but differ in their pharmacokinetic properties and receptor affinity.

**Why the Correct Answer is Right**
Dihydroergotamine is more potent as an α-adrenergic blocker, which means it has a greater ability to relax smooth muscle and dilate blood vessels. This is due to its higher affinity for α-adrenergic receptors. Additionally, dihydroergotamine is less potent as a vasoconstrictor, which is a desirable property in the treatment of migraine headaches. The vasoconstrictive effects of ergot alkaloids can lead to ischemic complications, so reducing this effect is beneficial. The α-adrenergic blockade and reduced vasoconstriction of dihydroergotamine contribute to its effectiveness and safety profile.

**Why Each Wrong Option is Incorrect**
**Option A:** Dihydroergotamine is not more potent as an oxytocic agent compared to ergotamine. Oxytocic agents stimulate uterine contractions, and both dihydroergotamine and ergotamine have oxytocic properties, but this is not the key difference between them.

**Option B:** While ergot alkaloids do have some antiemetic properties, this is not a unique characteristic of dihydroergotamine. The antiemetic effects of these compounds are thought to be due to their action on serotonin receptors, but this is not a distinguishing feature between dihydroergotamine and ergotamine.

**Option C:** Dihydroergotamine actually has low oral bioavailability, which makes it more commonly administered via parenteral routes (e.g., intravenous or intramuscular injection). This low bioavailability is due to extensive first-pass metabolism.

**Clinical Pearl / High-Yield Fact**
When choosing between dihydroergotamine and ergotamine for the treatment of migraines, consider the patient's specific needs and the potential risks associated with vasoconstriction. Dihydroergotamine's reduced vasoconstrictive effects make it a safer option for patients at risk of ischemic complications.

**✓ Correct Answer: D. It is more potent α-adrenergic blocker and less potent vasoconstrictor.**